企業プロフィール
Ardelyx 株価・ニュース・カタリスト
- ティッカー:
- ARDX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
4.06 USD (0.00%)
終値
最終更新: 2026年8月17日
1.36B USD
時価総額
株価変動の要因
As of Aug 17, 2026, ARDX was little changed and closed at $4.06. No new same-company headline was identified in the current news window.
企業概要
NHE3 Inhibition Platform
Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption.
IBSRELA and XPHOZAH
IBSRELA is approved for irritable bowel syndrome with constipation, while XPHOZAH is approved to lower serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response or intolerance to phosphate binders. Both products contain tenapanor.
Pipeline Expansion
The Phase 3 ACCEL trial is evaluating IBSRELA in adults with chronic idiopathic constipation. RDX10531 is a next-generation NHE3 inhibitor being explored across additional therapeutic applications.
今後のカタリスト
- Completion of enrollment in the Phase 3 ACCEL trial expected by year-end 2026.
- Topline ACCEL results expected in the second half of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。